Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KRAS Neoantigen Nanovaccine as Adjuvant Therapy for Colorectal and Pancreatic Cancer
NCT07353645Phase 2Recruiting
- Sponsor
- Nanjing Drum-Tower Hospital
- Start
- Mar 2026
- Primary completion
- Jan 2029
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in colorectal cancer (CRC) and pancreatic cancer (PC), sponsored by Nanjing Drum-Tower Hospital. Primary endpoint: Dose-limiting toxicities up to 5 years. Started Mar 2026; status: recruiting.
02
Conditions
colorectal cancer (CRC)pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT07353645.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07353645.